Share Twitter LinkedIn Facebook Email Joanne Lager, M.D. Head of Oncology Development, Sanofi Discusses Phase 2 Study Isatuximab & Dexamethasone At The 60th ASH Annual Meeting on Dec 1, 2018.
Teclistamab FDA Approval Biweekly Dosing Multiple Myeloma [3 KOL Interviews] Multiple Myeloma 13 Mins Read